{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:41:44Z","timestamp":1794559304293,"version":"4.9.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["PG\/18\/5033837"],"award-info":[{"award-number":["PG\/18\/5033837"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["AA\/18\/6\/34223"],"award-info":[{"award-number":["AA\/18\/6\/34223"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Development of cholesteryl ester transfer protein (CETP) inhibitors for coronary heart disease (CHD) has yet to deliver licensed medicines. To distinguish compound from drug target failure, we compared evidence from clinical trials and drug target Mendelian randomization of CETP protein concentration, comparing this to Mendelian randomization of proprotein convertase subtilisin\/kexin type 9 (PCSK9). We show that previous failures of CETP inhibitors are likely compound related, as illustrated by significant degrees of between-compound heterogeneity in effects on lipids, blood pressure, and clinical outcomes\u00a0observed in trials. On-target CETP inhibition, assessed through Mendelian randomization, is expected to reduce the risk of CHD, heart failure, diabetes, and chronic kidney disease, while increasing the risk of age-related macular degeneration. In contrast, lower PCSK9 concentration is anticipated to decrease the risk of CHD, heart failure, atrial fibrillation, chronic kidney disease, multiple sclerosis, and stroke, while potentially increasing the risk of Alzheimer\u2019s disease and asthma. Due to distinct effects on lipoprotein metabolite profiles, joint inhibition of CETP and PCSK9 may provide added benefit. In conclusion, we provide genetic evidence that CETP is an effective target for CHD prevention but with a potential on-target adverse effect on age-related macular degeneration.<\/jats:p>","DOI":"10.1038\/s41467-021-25703-3","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T08:05:45Z","timestamp":1634025945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1327-0424","authenticated-orcid":false,"given":"Amand F.","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1677-6025","authenticated-orcid":false,"given":"Nicholas B.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2993-6577","authenticated-orcid":false,"given":"Maria","family":"Gordillo-Mara\u00f1\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8851-0520","authenticated-orcid":false,"given":"Pimphen","family":"Charoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotios","family":"Drenos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4699-5627","authenticated-orcid":false,"given":"Mika","family":"Kivimaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6793-2262","authenticated-orcid":false,"given":"Deborah A.","family":"Lawlor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2786-1225","authenticated-orcid":false,"given":"Claudia","family":"Giambartolomei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olia","family":"Papacosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6211-2775","authenticated-orcid":false,"given":"Nishi","family":"Chaturvedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3409-1110","authenticated-orcid":false,"given":"Joshua C.","family":"Bis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2667-8624","authenticated-orcid":false,"given":"Christopher J.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goya","family":"Wannamethee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2079-4779","authenticated-orcid":false,"given":"Andrew","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie F.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5432-5271","authenticated-orcid":false,"given":"Alun D.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0924-3247","authenticated-orcid":false,"given":"Tom R.","family":"Gaunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis O.","family":"Mook-Kanamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-6030","authenticated-orcid":false,"given":"Magdalena","family":"Zwierzyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reecha","family":"Sofat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8365-0081","authenticated-orcid":false,"given":"Aroon D.","family":"Hingorani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3319-1937","authenticated-orcid":false,"given":"Chris","family":"Finan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"key":"25703_CR1","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins, R. et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388, 2532\u20132561 (2016).","journal-title":"Lancet"},{"key":"25703_CR2","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon, C. P. et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372, 2387\u20132397 (2015).","journal-title":"N. Engl. J. Med."},{"key":"25703_CR3","doi-asserted-by":"publisher","first-page":"1053 LP","DOI":"10.1136\/heartjnl-2017-312858","volume":"104","author":"AF Schmidt","year":"2018","unstructured":"Schmidt, A. F., Pearce, L. S., Wilkins, J. T., Casas, J. P. & Hingorani, A. D. Cochrane corner: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Heart 104, 1053 LP\u20131051055 (2018).","journal-title":"Heart"},{"key":"25703_CR4","doi-asserted-by":"crossref","unstructured":"Schmidt, A. F. et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 1\u201387 (2020).","DOI":"10.1002\/14651858.CD011748.pub3"},{"key":"25703_CR5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","volume":"36","author":"MV Holmes","year":"2015","unstructured":"Holmes, M. V. et al. Mendelian randomization of blood lipids for coronary heart disease. Eur. Heart J. 36, 539\u2013550 (2015).","journal-title":"Eur. Heart J."},{"key":"25703_CR6","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2009.1619","volume":"302","author":"Collaboration*, T. E. R. F.","year":"2009","unstructured":"Collaboration*, T. E. R. F. et al. Major lipids, apolipoproteins, and risk of vascular disease. J. Am. Med. Assoc. 302, 1993\u20132000 (2009).","journal-title":"J. Am. Med. Assoc."},{"key":"25703_CR7","first-page":"1108","volume":"366","author":"J White","year":"2016","unstructured":"White, J. et al. Association of lipid fractions with risks for coronary artery disease and diabetes. JAMA Cardiol. 366, 1108\u20131118 (2016).","journal-title":"JAMA Cardiol."},{"key":"25703_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"The HPS2-THRIVE Collaborative Group","year":"2014","unstructured":"The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N. Engl. J. Med. 371, 203\u2013212 (2014).","journal-title":"N. Engl. J. Med"},{"key":"25703_CR9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1161\/CIRCRESAHA.117.311978","volume":"122","author":"R Tall Alan","year":"2018","unstructured":"Tall Alan, R. & Rader Daniel, J. Trials and tribulations of CETP inhibitors. Circ. Res. 122, 106\u2013112 (2018).","journal-title":"Circ. Res."},{"key":"25703_CR10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jacc.2018.10.072","volume":"73","author":"J Armitage","year":"2019","unstructured":"Armitage, J., Holmes, M. V. & Preiss, D. Cholesteryl ester transfer protein inhibition for preventing cardiovascular events. J. Am. Coll. Cardiol. 73, 477\u2013487 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"25703_CR11","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","volume":"377","author":"The HPS3\/TIMI55\u2013REVEAL Collaborative Group.","year":"2017","unstructured":"The HPS3\/TIMI55\u2013REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. N. Engl. J. Med. 377, 1217\u20131227 (2017).","journal-title":"N. Engl. J. Med."},{"key":"25703_CR12","doi-asserted-by":"publisher","unstructured":"Mulick, A. R. et al. High density lipoprotein pathway as a therapeutic target for coronary heart disease: individual participant meta-analysis in 28,597 individuals with 4197 coronary events. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.03.02.19010173 (2020).","DOI":"10.1101\/2020.03.02.19010173"},{"key":"25703_CR13","doi-asserted-by":"publisher","unstructured":"Joshi, R. et al. Triglyceride-containing lipoprotein sub-fractions and risk of coronary heart disease and stroke: a prospective analysis in 11,560 adults. Eur. J. Prev. Cardiol. https:\/\/doi.org\/10.1177\/2047487319899621 (2020).","DOI":"10.1177\/2047487319899621"},{"key":"25703_CR14","doi-asserted-by":"publisher","first-page":"e002034","DOI":"10.1161\/CIRCGEN.117.002034","volume":"11","author":"LL Blauw","year":"2018","unstructured":"Blauw, L. L. et al. CETP (cholesteryl ester transfer protein) concentration: a genome-wide association study followed by mendelian randomization on coronary artery disease. Circ. Genom. Precis. Med. 11, e002034 (2018).","journal-title":"Circ. Genom. Precis. Med."},{"key":"25703_CR15","unstructured":"Merck halts development of anacetrapib. https:\/\/www.healio.com\/news\/cardiology\/20171012\/merck-halts-development-of-anacetrapib."},{"key":"25703_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40262-013-0071-8","volume":"52","author":"AH Mohammadpour","year":"2013","unstructured":"Mohammadpour, A. H. & Akhlaghi, F. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective. Clin. Pharmacokinet. 52, 615\u2013626 (2013).","journal-title":"Clin. Pharmacokinet."},{"key":"25703_CR17","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2165\/11599310-000000000-00000","volume":"72","author":"DG Johns","year":"2012","unstructured":"Johns, D. G., Duffy, J., Fisher, T., Hubbard, B. K. & Forrest, M. J. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors. Drugs 72, 491\u2013507 (2012).","journal-title":"Drugs"},{"key":"25703_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.25642","volume":"87","author":"DM Williams","year":"2020","unstructured":"Williams, D. M., Finan, C., Schmidt, A. F., Burgess, S. & Hingorani, A. D. Lipid lowering and Alzheimer disease risk: a Mendelian randomization study. Ann. Neurol. 87, 30\u201339 (2020).","journal-title":"Ann. Neurol."},{"key":"25703_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16969-0","volume":"11","author":"AF Schmidt","year":"2020","unstructured":"Schmidt, A. F. et al. Genetic drug target validation using Mendelian randomisation. Nat. Commun. 11, 3255 (2020).","journal-title":"Nat. Commun."},{"key":"25703_CR20","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jama.2017.11467","volume":"318","author":"BA Ference","year":"2017","unstructured":"Ference, B. A. et al. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. J. Am. Med. Assoc. 318, 947\u2013956 (2017).","journal-title":"J. Am. Med. Assoc."},{"key":"25703_CR21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41431-018-0301-5","volume":"27","author":"LL Blauw","year":"2019","unstructured":"Blauw, L. L. et al. Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile. Eur. J. Hum. Genet. 27, 422\u2013431 (2019).","journal-title":"Eur. J. Hum. Genet."},{"key":"25703_CR22","doi-asserted-by":"publisher","first-page":"e3000572","DOI":"10.1371\/journal.pbio.3000572","volume":"17","author":"J Kettunen","year":"2019","unstructured":"Kettunen, J. et al. Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition. PLOS Biol. 17, e3000572 (2019).","journal-title":"PLOS Biol."},{"key":"25703_CR23","doi-asserted-by":"publisher","unstructured":"Tikkanen, E. et al. Metabolic biomarkers for peripheral artery disease compared with coronary artery disease: lipoprotein and metabolite profiling of 31,657 individuals from five prospective cohorts. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.07.24.20158675 (2020).","DOI":"10.1101\/2020.07.24.20158675"},{"key":"25703_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2015.08.042","volume":"243","author":"PN Hopkins","year":"2015","unstructured":"Hopkins, P. N., Pottala, J. V. & Nanjee, M. N. A comparative study of four independent methods to measure LDL particle concentration. Atherosclerosis 243, 99\u2013106 (2015).","journal-title":"Atherosclerosis"},{"key":"25703_CR25","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","volume":"375","author":"BA Ference","year":"2016","unstructured":"Ference, B. A. et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N. Engl. J. Med. 375, 2144\u20132153 (2016).","journal-title":"N. Engl. J. Med."},{"key":"25703_CR26","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1093\/eurheartj\/ehx462","volume":"39","author":"BA Ference","year":"2017","unstructured":"Ference, B. A. How to use Mendelian randomization to anticipate the results of randomized trials. Eur. Heart J. 39, 360\u2013362 (2017).","journal-title":"Eur. Heart J"},{"key":"25703_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-1-6","volume":"1","author":"AJ Vickers","year":"2001","unstructured":"Vickers, A. J. The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. BMC Med. Res. Methodol. 1, 6 (2001).","journal-title":"BMC Med. Res. Methodol."},{"key":"25703_CR28","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins, J. P. T. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539\u20131558 (2002).","journal-title":"Stat. Med."},{"key":"25703_CR29","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jclinepi.2014.02.008","volume":"67","author":"AF Schmidt","year":"2014","unstructured":"Schmidt, A. F. et al. Exploring interaction effects in small samples increases rates of false-positive and false-negative findings: Results from a systematic review and simulation study. J. Clin. Epidemiol. 67, 821\u2013829 (2014).","journal-title":"J. Clin. Epidemiol."},{"key":"25703_CR30","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1177\/0962280216680652","volume":"27","author":"AF Schmidt","year":"2016","unstructured":"Schmidt, A. F. & Groenwold, R. H. H. Adjusting for bias in unblinded randomized controlled trials. Stat. Methods Med. Res. 27, 2413\u20132427 (2016).","journal-title":"Stat. Methods Med. Res"},{"key":"25703_CR31","unstructured":"Willer, C. J. et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 40 (2008)."},{"key":"25703_CR32","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/aje\/kwv017","volume":"181","author":"S Burgess","year":"2015","unstructured":"Burgess, S., Dudbridge, F. & Thompson, S. G. Re: \u201cmultivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects\u201d. Am. J. Epidemiol. 181, 290\u2013291 (2015).","journal-title":"Am. J. Epidemiol."},{"key":"25703_CR33","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/ije\/dyr036","volume":"40","author":"S Burgess","year":"2011","unstructured":"Burgess, S. & Thompson, S. G. Avoiding bias from weak instruments in Mendelian randomization studies. Int. J. Epidemiol. 40, 755\u2013764 (2011).","journal-title":"Int. J. Epidemiol."},{"key":"25703_CR34","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/gepi.22077","volume":"41","author":"S Burgess","year":"2017","unstructured":"Burgess, S., Zuber, V., Valdes-Marquez, E., Sun, B. B. & Hopewell, J. C. Mendelian randomization with fine-mapped genetic data: choosing from large numbers of correlated instrumental variables. Genet. Epidemiol. 41, 714\u2013725 (2017).","journal-title":"Genet. Epidemiol."},{"key":"25703_CR35","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1002\/sim.6835","volume":"35","author":"S Burgess","year":"2016","unstructured":"Burgess, S., Dudbridge, F. & Thompson, S. G. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. Stat. Med. 35, 1880\u20131906 (2016).","journal-title":"Stat. Med."},{"key":"25703_CR36","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1002\/sim.7221","volume":"36","author":"J Bowden","year":"2017","unstructured":"Bowden, J. et al. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat. Med. 36, 1783\u20131802 (2017).","journal-title":"Stat. Med."},{"key":"25703_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/CIRCGEN.117.001992","volume":"11","author":"J Pott","year":"2018","unstructured":"Pott, J. et al. Genetic regulation of PCSK9 (proprotein convertase subtilisin\/kexin type 9) plasma levels and its impact on atherosclerotic vascular disease phenotypes. Circ. Genomic Precis. Med. 11, 1\u201311 (2018).","journal-title":"Circ. Genomic Precis. Med"},{"key":"25703_CR38","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/ng.3396","volume":"47","author":"M Nikpay","year":"2015","unstructured":"Nikpay, M. et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat. Genet. 47, 1121\u20131130 (2015).","journal-title":"Nat. Genet."},{"key":"25703_CR39","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41588-018-0058-3","volume":"50","author":"R Malik","year":"2018","unstructured":"Malik, R. et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat. Genet. 50, 524\u2013537 (2018).","journal-title":"Nat. Genet."},{"key":"25703_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13993-7","volume":"11","author":"S Shah","year":"2020","unstructured":"Shah, S. et al. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nat. Commun. 11, 1\u201312 (2020).","journal-title":"Nat. Commun."},{"key":"25703_CR41","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/s41588-018-0171-3","volume":"50","author":"JB Nielsen","year":"2018","unstructured":"Nielsen, J. B. et al. Biobank-driven genomic discovery yields new insight into atrial fibrillation biology. Nat. Genet. 50, 1234\u20131239 (2018).","journal-title":"Nat. Genet."},{"key":"25703_CR42","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/ng.2802","volume":"45","author":"JC Lambert","year":"2013","unstructured":"Lambert, J. C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease. Nat. Genet. 45, 1452\u20131458 (2013).","journal-title":"Nat. Genet."},{"key":"25703_CR43","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/ng.3448","volume":"48","author":"LG Fritsche","year":"2016","unstructured":"Fritsche, L. G. et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat. Genet. 48, 134\u2013143 (2016).","journal-title":"Nat. Genet."},{"key":"25703_CR44","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.ophtha.2017.03.042","volume":"124","author":"S Burgess","year":"2017","unstructured":"Burgess, S. & Davey Smith, G. Mendelian randomization implicates high-density lipoprotein cholesterol-associated mechanisms in etiology of age-related macular degeneration. Ophthalmology 124, 1165\u20131174 (2017).","journal-title":"Ophthalmology"},{"key":"25703_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms11122","volume":"7","author":"J Kettunen","year":"2016","unstructured":"Kettunen, J. et al. Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. Nat. Commun. 7, 1\u20139 (2016).","journal-title":"Nat. Commun."},{"key":"25703_CR46","doi-asserted-by":"publisher","first-page":"e71345","DOI":"10.1371\/journal.pone.0071345","volume":"8","author":"T Shah","year":"2013","unstructured":"Shah, T. et al. Population genomics of cardiometabolic traits: design of the University College London-London School of Hygiene and Tropical Medicine-Edinburgh-Bristol (UCLEB) Consortium. PloS ONE 8, e71345 (2013).","journal-title":"PloS ONE"},{"key":"25703_CR47","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/s41588-018-0205-x","volume":"50","author":"E Evangelou","year":"2018","unstructured":"Evangelou, E. et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat. Genet. 50, 1412\u20131425 (2018).","journal-title":"Nat. Genet."},{"key":"25703_CR48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCGENETICS.108.829747","volume":"2","author":"BM Psaty","year":"2009","unstructured":"Psaty, B. M. et al. Cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium: design of prospective meta-analyses of genome-wide association studies from five cohorts. Circ. Cardiovasc. Genet. 2, 73\u201380 (2009).","journal-title":"Circ. Cardiovasc. Genet."},{"key":"25703_CR49","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/s41588-019-0407-x","volume":"51","author":"M Wuttke","year":"2019","unstructured":"Wuttke, M. et al. A catalog of genetic loci associated with kidney function from analyses of a million individuals. Nat. Genet. 51, 957\u2013972 (2019).","journal-title":"Nat. Genet."},{"key":"25703_CR50","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41588-018-0302-x","volume":"51","author":"JA Morris","year":"2019","unstructured":"Morris, J. A. et al. An atlas of genetic influences on osteoporosis in humans and mice. Nat. Genet. 51, 258\u2013266 (2019).","journal-title":"Nat. Genet."},{"key":"25703_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-02088-w","volume":"9","author":"G Davies","year":"2018","unstructured":"Davies, G. et al. Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nat. Commun. 9, 1\u201316 (2018).","journal-title":"Nat. Commun."},{"key":"25703_CR52","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41588-018-0084-1","volume":"50","author":"A Mahajan","year":"2018","unstructured":"Mahajan, A. et al. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nat. Genet. 50, 559\u2013571 (2018).","journal-title":"Nat. Genet."},{"key":"25703_CR53","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S2213-2600(18)30389-8","volume":"7","author":"N Shrine","year":"2019","unstructured":"Shrine, N. et al. Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study. Lancet Respir. Med. 7, 20\u201334 (2019).","journal-title":"Lancet Respir. Med."},{"key":"25703_CR54","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature11582","volume":"491","author":"L Jostins","year":"2012","unstructured":"Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119\u2013124 (2012).","journal-title":"Nature"},{"key":"25703_CR55","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/ng.717","volume":"42","author":"A Franke","year":"2010","unstructured":"Franke, A. et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn\u2019s disease susceptibility loci. Nat. Genet. 42, 1118\u20131125 (2010).","journal-title":"Nat. Genet."},{"key":"25703_CR56","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/ng.764","volume":"43","author":"CA Anderson","year":"2011","unstructured":"Anderson, C. A. et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat. Genet. 43, 246\u2013252 (2011).","journal-title":"Nat. Genet."},{"key":"25703_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/science.aav7188","volume":"365","author":"International Multiple Sclerosis Genetics Consortium","year":"2019","unstructured":"Consortium, I. M. S. G. International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 365, 1\u201311 (2019).","journal-title":"Science"},{"key":"25703_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer, W. Conducting meta-analyses in R with the metafor package. J. Stat. Softw. 36, 1\u201348 (2010).","journal-title":"J. Stat. Softw."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25703-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25703-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25703-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T10:11:58Z","timestamp":1669975918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25703-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["25703"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-25703-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.09.07.20189571","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-78818\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,24]]},"assertion":[{"value":"16 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.F.S. has received Servier funding for unrelated work. M.Z. conducted this research as an employee of BenevolentAI. Since completing the work M.Z. is now a full-time employee of GlaxoSmithKline. Since completing the work C.J.O. is now a full-time employee of Novartis Institutes for Biomedical Research. D.A.L. has received support from Roche Diagnostics and Medtronic Ltd. for research unrelated to this paper. T.R.G. receives funding from GlaxoSmithKline and Biogen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5640"}}